Richard M. Marais, PhD, FMedSci, FRS

Richard M. Marais, PhD, FMedSci, FRS

Cancer Research UK Manchester Institute

Research Interests

Cell signaling in melanoma; the role of oncogenic BRAF in melanoma cells; signaling downstream of BRAF using RNA interference and gene-expression arrays approaches; the role of cyclic nucleotide signaling in proliferation and migration; the role of metabolism in melanoma cell survival and proliferation; how different mutations activate RAF proteins and how BRAF regulates CRAF; mouse models of melanoma driven by oncogenic BRAF and oncogenic RAS; the development of novel BRAF drugs and therapeutic strategies for the treatment of melanoma; gene therapy approaches for the treatment of cancer.

Current Affiliations

Director and Senior Group Leader of Molecular Oncology Group, Cancer Research UK Manchester Institute; Centre Colead, Cancer Research UK Lung Cancer Centre of Excellence; Scientific Codirector, Belfast-Manchester Movember Centre of Excellence; Centre Colead, CRUK Manchester Centre; Professor of Molecular Oncology, University of Manchester, Manchester, England.

Previous Positions

Division Head, Division of Cancer Biology (2011-2012); Deputy Chair, Section of Cell and Molecular Biology (2008-2011); Professor of Molecular Oncology (2007-2012); and Team Leader, Signal Transduction Team (1998-2012), The Institute of Cancer Research, London, England.

Postdoctoral Training

Independent Postdoctoral Research Fellow, The Institute of Cancer Research, London (1993-1998); Postdoctoral Research Fellow, Imperial Cancer Research Fund, London (1989-1992), London, England.

Selected AACR Service, Honors, and Awards

Vice Chair (2018-2019), Cochair (2014-2015), and Member (2015-2016, 2012-2013), Annual Meeting Program Committee; Cochair, EACR-AACR-ISCR Special Conference, Jerusalem, Israel (2018); Member, Editorial Board (2016-2019), Senior Editor (2007-2009) and Associate Editor (2005-2007), Cancer Research; Member, Board of Directors (2015-2018); Cochair, Annual Meeting Education Committee (2015); Scientific Editor, Cancer Discovery (2014-present); Cochair, Stand Up To Cancer, Cancer Research UK Translational Research Fellowship Joint Scientific Advisory Committee (2014-present); Member, Cancer Immunology Working Group (2013-present); Member, Publications Committee (2012-2015); Faculty and Program Committee Member, Educational Workshop, “Translational Research for Basic Scientist” (2012-2014); Recipient, AACR Team Science Award (2012); Chair, Research Grant Review Committee (2012); Keynote Speaker, Special Conference, “Molecularly Targeted Therapies: Mechanisms of Resistance” (2012); Chair (2010) and Member (2008), Landon Foundation-AACR INNOVATOR Award for International Collaboration in Cancer Research Committee; Member, Scientific Program Committee, Translational Cancer Medicine Meeting (2010); Member, Pezcoller Foundation-AACR International Award for Cancer Research Committee (2007, 2015).

Selected Non-AACR Service, Honors, and Awards

Elected Fellow, The Royal Society (2018); Treasurer (2018-2020), Past President (2016-2018), President (2014-2016), President-Elect (2013-2014), and Secretary General (2004-2013), European Association for Cancer Research; Recipient, Society for Melanoma Research Outstanding Research Award (2017); Recipient, ARC Foundation Léopold Griffuel Award in Translational and Clinical Research (2017); Chair, Joint Scientific Advisory Committee, SU2C-CRUK-Lustgarten Foundation Pancreatic Cancer Dream Team (2016-present); Recipient, Worldwide Cancer Research Colin Thomson Memorial Medal (2016); Elected Member, Academia Europaea (2015); Member, Board of Directors, European CanCer Organisation (2014-2016); Recipient, The Dr. Melvin L. and Dr. Sylvia F. Griem Lectureship in Molecular and Cellular Oncology, The University of Chicago Comprehensive Cancer Center (2014); Member, Editorial Board, Cancer Cell (2013-present); Trustee and Professional Member, Melanoma Focus (2012-present); Member, Society for Melanoma Research (2012-present); Recipient, Society for Melanoma Research Estella Medrano Memorial Award (2011); Member, Scientific Advisory Board, The Melanoma Research Alliance (2009-present); Elected Member, Excellence in the Life Sciences (2009); Elected Fellow, European Academy of Cancer Sciences (2009); Member, Scientific Advisory Board, The Harry J. Lloyd Charitable Trust (2007-present); Elected Fellow, Academy of Medical Sciences (2007); Member, National Cancer Research Institute Melanoma Clinical Studies Group (2004-present).


PhD, Biochemistry, Ludwig Institute for Cancer Research, London, England (1989); BSc, Genetics and Microbiology, University College, London, England (1985).